Efficacy and Safety of Two Different Brolucizumab 6 mg Dosing Regimens in Neovascular Age-related Macular Degeneration
Clinical trial NCT04679935 · COMPLETED
Trial details
- NCT number
- NCT04679935
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 4
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-13
- Primary completion
- 2024-01-31
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.